A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer
Gottfried E. Konecny, N. J. Finkler, P. Lee et al. · Gynecologic Oncology · 2012
Cited by 1 works. doi:10.1016/j.ygyno.2011.12.192